State Street SPDR S&P Biotech ETF (XBI)
Market Price (9/17/2026): $156.38
State Street SPDR S&P Biotech ETF (XBI)
Market Price (9/17/2026): $156.38
Key Takeaways
- XBI has returned +26.4% YTD vs +10.9% for SPY; +65.1% over the past 12 months (SPY +15.2%). details →
- Priced in gold, XBI has returned -10.9% over the past 3 years, vs +101.0% in dollars — its dollar gains have lagged gold. details →
- Over the past month, XBI has seen net outflows of −$170M (−1.5% of assets). details →
- Only 32% of XBI's portfolio (by weight) is currently profitable, vs 98% for SPY. details →
- XBI's top 10 holdings represent 16% of the fund vs 37% for SPY — a more diversified portfolio. details →
Asset Allocation with XBI
Valuation & Yield
| Forward [4,5] | Now | Historical (CYE & TTM) | |||||
|---|---|---|---|---|---|---|---|
| 9/30/27 | 9/17/26 | 2025 | 2024 | 2023 | 2022 | 2021 | |
| Share Price CYE | $154.18 | $121.93 | $89.72 | $88.83 | $82.56 | $111.36 | |
| Dividend/Share TTM | $0.43 | $0.45 | $0.13 | $0.02 | $0.00 | $0.04 | |
Valuation [1] | |||||||
| P/S | 7.30 | 9.43 | 8.29 | 7.51 | 8.07 | 5.00 | 20.33 |
| P/E | 23.26 | 20.17 | 22.17 | 28.48 | 16.21 | 11.20 | |
| P/E (Non-GAAP) [2] | 44.09 | 60.53 | 48.30 | 46.74 | 109.17 | 107.58 | 93.05 |
| P/FCF | — | — | — | — | — | — | |
Yields TTM | |||||||
| Earnings Yield | 2.27% | 4.30% | 4.96% | 4.51% | 3.51% | 6.17% | 8.93% |
| Dividend Yield | 0.28% | 0.28% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% |
| Total Yield (TY) | 2.55% | 4.58% | 5.32% | 4.66% | 3.53% | 6.17% | 8.96% |
Risk Premium [3] | |||||||
| Risk Free Rate (Rf) | 5.00% | 5.00% | 4.18% | 4.58% | 3.88% | 3.88% | 1.52% |
| Risk Prem. (TY - Rf) | -2.45% | -0.42% | 1.14% | 0.08% | -0.35% | 2.29% | 7.44% |
Growth Rates [6] | |||||||
| Sales Growth | 16.0% | 1.4% | 25.3% | 15.0% | -10.2% | 8.4% | |
| Earnings Growth [7] | |||||||
[1] P/E uses the aggregate method over profitable constituents; P/FCF aggregates net free cash flow across all constituents (negative-FCF names reduce it); P/S uses all constituents. Ratios reflect current ETF holdings at current weights. P/FCF has no Forward column (no analyst FCF estimate).
[2] P/E (Non-GAAP) uses analyst consensus net income (adjusted basis) for all periods. The standard P/E row above uses GAAP net income.
[3] The premium above the risk free rate (US 10Y) offered by the investment. Negative premiums can indicate stretched valuations.
Show more
Top 20 Holdings for XBI
Total Weights Top 5: 9.0% | Top 10: 15.9% | Top 20: 28.5%
| Ticker | Holding | ETF Weight | Sales Weight | Earnings Weight | Fwd P/S | Fwd P/E | Fwd Sales Growth | Fwd Earnings Growth |
|---|---|---|---|---|---|---|---|---|
| Total | 70.61% | 100.00% | 100.00% | 6.9 | 42.3 | +16.0% | +13.6% | |
| Top 20 | 19.50% | 11.15% | 12.78% | 15.2 | 54.5 | +19.0% | -4.5% | |
| MRNA | Moderna | 2.87% | 1.26% | — | 25.0 | — | +13.8% | — |
| TWST | Twist Bioscience | 1.81% | 1.00% | — | 16.4 | — | +19.3% | — |
| HALO | Halozyme Therapeutics | 1.47% | 2.20% | 4.74% | 6.4 | 10.4 | +11.5% | +22.3% |
| NTRA | Natera | 1.46% | 0.91% | — | 14.8 | — | +19.9% | — |
| KYMR | Kymera Therapeutics | 1.44% | 0.15% | — | 202.2 | — | -61.8% | — |
| TVTX | Travere Therapeutics | 1.40% | 1.60% | — | 6.0 | 13.5 | +49.4% | — |
| ROIV | Roivant Sciences | 1.39% | 0.00% | — | 123.3 | — | +675.5% | — |
| ORKA | Oruka Therapeutics | 1.38% | — | — | — | — | — | — |
| RVMD | Revolution Medicines | 1.36% | — | — | — | — | — | — |
| PRAX | Praxis Precision Medicines | 1.36% | — | — | — | — | — | — |
| INSM | Insmed | 1.34% | 0.66% | — | 10.2 | 532.3 | +59.8% | — |
| PTGX | Protagonist Therapeutics | 1.33% | 0.46% | 1.16% | 33.6 | 147.3 | -64.5% | -107.7% |
| DNTH | Dianthus Therapeutics | 1.31% | 0.00% | — | 2,883.5 | — | +7.7% | — |
| REGN | Regeneron Pharmaceuticals | 1.27% | 2.85% | 6.88% | 4.4 | 12.4 | +9.1% | +12.7% |
| CGON | CG Oncology | 1.27% | 0.01% | — | 106.2 | — | +1,765.9% | — |
| PCVX | Vaxcyte | 1.25% | — | — | — | — | — | — |
| SMMT | Summit Therapeutics | 1.23% | — | — | — | — | — | — |
| SRRK | Scholar Rock | 1.22% | — | — | — | — | — | — |
| ERAS | Erasca | 1.16% | — | — | — | — | — | — |
| RLAY | Relay Therapeutics | 1.16% | 0.04% | — | 237.9 | — | +70.1% | — |
[2] Forward P/S and P/E ratios use consensus sales and earnings for the 12 months ending 9/30/27. Individual constituent FY1 and FY2 consensus figures adjusted to align with 9/30/27.
[3] Forward Sales and Non-GAAP Earnings Growth are calculated as next fiscal year (FY2) consensus growth over current fiscal year (FY1) consensus. They are not derived from the forward P/S and P/E multiples shown.
Performance for XBI Top Holdings
| Ticker | Holding | Weight | Mkt Price9/16 | 1D Rtn | 1M Rtn | YTD Rtn | 1Y Rtn | 3Y Rtn | 5Y Rtn | 10Y Rtn |
|---|---|---|---|---|---|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 100.00% | 154.18 | 0.1% | -3.4% | 26.4% | 65.1% | 101.0% | 16.7% | 141.4% |
| MRNA | Moderna | 2.87% | 145.62 | 1.3% | 125.9% | 393.8% | 486.2% | 27.1% | -66.1% | |
| TWST | Twist Bioscience | 1.81% | 143.07 | 3.6% | 15.0% | 351.0% | 428.3% | 582.9% | 17.5% | |
| HALO | Halozyme Therapeutics | 1.47% | 108.44 | 2.1% | 5.3% | 61.1% | 43.0% | 176.5% | 157.9% | 805.2% |
| NTRA | Natera | 1.46% | 345.34 | -1.6% | 9.9% | 50.7% | 97.3% | 570.6% | 173.3% | 3,279.1% |
| KYMR | Kymera Therapeutics | 1.44% | 116.33 | 2.8% | -4.2% | 49.5% | 138.5% | 510.7% | 84.8% | |
| TVTX | Travere Therapeutics | 1.40% | 63.48 | 1.6% | -0.1% | 66.1% | 178.8% | 363.7% | 182.0% | 161.8% |
| ROIV | Roivant Sciences | 1.39% | 39.57 | 0.2% | 9.2% | 82.4% | 179.1% | 250.5% | 297.3% | |
| ORKA | Oruka Therapeutics | 1.38% | 93.55 | 1.5% | -17.0% | 208.6% | 527.9% | 607.1% | 367.6% | -72.3% |
| RVMD | Revolution Medicines | 1.36% | 195.92 | -4.4% | -7.6% | 146.0% | 338.3% | 516.9% | 527.3% | |
| PRAX | Praxis Precision Medicines | 1.36% | 308.99 | -1.2% | -17.9% | 4.8% | 635.7% | 1,382.0% | 3.2% | |
| INSM | Insmed | 1.34% | 122.58 | 2.2% | -4.5% | -29.6% | -15.3% | 360.7% | 357.7% | 741.3% |
| PTGX | Protagonist Therapeutics | 1.33% | 142.84 | -0.4% | -9.9% | 63.5% | 143.8% | 698.0% | 714.8% | 896.8% |
| DNTH | Dianthus Therapeutics | 1.31% | 102.49 | -2.2% | -10.8% | 148.7% | 173.5% | 686.0% | 1,215.7% | |
| REGN | Regeneron Pharmaceuticals | 1.27% | 774.61 | 0.1% | -3.8% | 0.7% | 35.4% | -5.0% | 19.9% | 91.4% |
| CGON | CG Oncology | 1.27% | 74.12 | 2.2% | -3.9% | 78.5% | 107.3% | |||
| PCVX | Vaxcyte | 1.25% | 58.77 | -0.7% | -2.4% | 27.4% | 88.2% | 13.6% | 131.7% | |
| SMMT | Summit Therapeutics | 1.23% | 17.30 | -0.6% | 35.4% | -1.1% | -4.5% | 825.1% | 171.2% | 190.8% |
| SRRK | Scholar Rock | 1.22% | 49.37 | -1.3% | -5.1% | 12.1% | 52.7% | 671.4% | 21.9% | |
| ERAS | Erasca | 1.16% | 15.36 | -5.5% | -16.0% | 312.9% | 798.2% | 495.3% | -20.9% | |
| RLAY | Relay Therapeutics | 1.16% | 18.84 | -0.7% | -8.9% | 122.7% | 356.2% | 101.1% | -49.2% |
Guidance Updates for XBI Top Holdings
| Ticker | Company | Earnings Date | Guidance Metric | Midpoint Value | % Change | Guidance Change | |
|---|---|---|---|---|---|---|---|
| HALO_8062026 | HALO | Halozyme Therapeutics | 8/6/2026 | 2026 Total Revenue | 1.87 Bil | 6.4% | RaisedRaised Prior Guidance of 1.76 Bil for 2026 |
| INSM_8062026 | INSM | Insmed | 8/6/2026 | 2026 BRINSUPRI Revenue | 1.32 Bil | 32.5% | RaisedRaised Prior Guidance of 1.00 Bil for 2026 |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XBI Return | -20% | -26% | 8% | 1% | 36% | 26% | 10% |
| Peers Return | 33% | -5% | 32% | 13% | 33% | 39% | 246% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| XBI Win Rate | 33% | 50% | 50% | 50% | 67% | 78% | |
| Peers Win Rate | 63% | 48% | 58% | 57% | 67% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 44% | |
Max Drawdowns [4] | |||||||
| XBI Max Drawdown | -37% | -46% | -30% | -20% | -26% | -11% | |
| Peers Max Drawdown | -18% | -35% | -16% | -18% | -27% | -20% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SMH, SOXX, IBB, ITA, XOP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/16/2026 (YTD)
Sharpe Ratios Compared
One measure of reward vs. risk is a Sharpe ratio. A higher ratio indicates better risk-adjusted returns. Most funds have Sharpe ratios < 1.0.
Results as of 8312026.How Low Can It Go
| Event | XBI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.9% | -9.5% |
| % Gain to Breakeven | 29.7% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -14.5% | -6.7% |
| % Gain to Breakeven | 17.0% | 7.1% |
| Time to Breakeven | 48 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -45.6% | -24.5% |
| % Gain to Breakeven | 83.8% | 32.4% |
| Time to Breakeven | 1290 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.9% | -33.7% |
| % Gain to Breakeven | 49.1% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.0% | 23.8% |
| Time to Breakeven | 351 days | 105 days |
In The Past
State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | XBI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.9% | -9.5% |
| % Gain to Breakeven | 29.7% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -45.6% | -24.5% |
| % Gain to Breakeven | 83.8% | 32.4% |
| Time to Breakeven | 1290 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.9% | -33.7% |
| % Gain to Breakeven | 49.1% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.0% | 23.8% |
| Time to Breakeven | 351 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -21.4% | -3.7% |
| % Gain to Breakeven | 27.2% | 3.9% |
| Time to Breakeven | 11 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -42.3% | -12.2% |
| % Gain to Breakeven | 73.2% | 13.9% |
| Time to Breakeven | 497 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -26.7% | -17.9% |
| % Gain to Breakeven | 36.5% | 21.8% |
| Time to Breakeven | 172 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -29.1% | -53.4% |
| % Gain to Breakeven | 41.0% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Current Dip Buy Opportunities Across ETFs
ETFs currently down 5% or more from trailing 6M peaks.
| Ticker | Name | Dip % | Mkt Price | Price Date | Peak Price | Peak Date | # Days |
|---|---|---|---|---|---|---|---|
| DIA | State Street SPDR Dow Jones Industrial Average ETF Trust | -5.1% | 515.22 | 9162026 | 542.81 | 8052026 | 42 |
| QQQ | Invesco QQQ Trust, Series 1 | -5.6% | 704.72 | 9162026 | 746.16 | 6022026 | 106 |
| QQQM | Invesco NASDAQ 100 ETF | -5.5% | 290.20 | 9162026 | 307.23 | 6022026 | 106 |
| QQEW | First Trust Nasdaq-100 Select Equal Weight ETF | -6.6% | 155.99 | 9162026 | 167.03 | 8132026 | 34 |
| IJH | iShares Core S&P Mid-Cap ETF | -7.5% | 72.80 | 9162026 | 78.67 | 8162026 | 31 |
| VO | Vanguard Mid-Cap ETF | -5.8% | 79.54 | 9162026 | 84.46 | 8162026 | 31 |
| IWR | iShares Russell Mid-Cap ETF | -6.1% | 107.83 | 9162026 | 114.82 | 8162026 | 31 |
| MDY | State Street SPDR S&P MIDCAP 400 ETF Trust | -7.1% | 665.88 | 9162026 | 716.91 | 8162026 | 31 |
| SCHM | Schwab U.S. Mid-Cap ETF | -6.3% | 34.56 | 9162026 | 36.87 | 6302026 | 78 |
| IVOO | Vanguard S&P Mid-Cap 400 ETF | -7.1% | 123.63 | 9162026 | 133.08 | 8162026 | 31 |
| IJR | iShares Core S&P Small-Cap ETF | -7.3% | 139.46 | 9162026 | 150.44 | 8162026 | 31 |
| VB | Vanguard Small-Cap ETF | -6.6% | 288.98 | 9162026 | 309.29 | 8162026 | 31 |
| IWM | iShares Russell 2000 ETF | -6.9% | 283.92 | 9162026 | 305.09 | 8162026 | 31 |
| SCHA | Schwab U.S. Small-Cap ETF | -8.5% | 33.06 | 9162026 | 36.13 | 6302026 | 78 |
| VTWO | Vanguard Russell 2000 ETF | -6.7% | 115.07 | 9162026 | 123.31 | 8162026 | 31 |
| DFAS | Dimensional U.S. Small Cap ETF | -6.1% | 79.29 | 9162026 | 84.48 | 8162026 | 31 |
| ESML | iShares ESG Aware MSCI USA Small-Cap ETF | -6.6% | 52.92 | 9162026 | 56.64 | 8162026 | 31 |
| NUSC | Nuveen ESG Small-Cap ETF | -6.9% | 49.57 | 9162026 | 53.27 | 8162026 | 31 |
| IWF | iShares Russell 1000 Growth ETF | -6.3% | 120.54 | 9162026 | 128.66 | 6012026 | 107 |
| VONG | Vanguard Russell 1000 Growth ETF | -6.1% | 124.23 | 9162026 | 132.35 | 6012026 | 107 |
| AKRE | Akre Focus ETF | -9.2% | 56.19 | 9162026 | 61.85 | 8302026 | 17 |
| IWP | iShares Russell Mid-Cap Growth ETF | -8.2% | 135.56 | 9162026 | 147.70 | 8172026 | 30 |
| VOT | Vanguard Mid-Cap Growth ETF | -7.8% | 289.52 | 9162026 | 314.02 | 8162026 | 31 |
| IJK | iShares S&P Mid-Cap 400 Growth ETF | -8.4% | 109.14 | 9162026 | 119.11 | 8172026 | 30 |
| MDYG | State Street SPDR S&P 400 Mid Cap Growth ETF | -8.3% | 104.26 | 9162026 | 113.69 | 8172026 | 30 |
| IWO | iShares Russell 2000 Growth ETF | -8.7% | 361.11 | 9162026 | 395.65 | 8162026 | 31 |
| VBK | Vanguard Small-Cap Growth ETF | -8.5% | 335.15 | 9162026 | 366.24 | 8172026 | 30 |
| IJT | iShares S&P Small-Cap 600 Growth ETF | -8.9% | 163.20 | 9162026 | 179.07 | 8042026 | 43 |
| SLYG | State Street SPDR S&P 600 Small Cap Growth ETF | -8.6% | 109.17 | 9162026 | 119.50 | 8042026 | 43 |
| IWS | iShares Russell Mid-Cap Value ETF | -5.5% | 163.91 | 9162026 | 173.44 | 8162026 | 31 |
| IJJ | iShares S&P Mid-Cap 400 Value ETF | -6.4% | 141.98 | 9162026 | 151.67 | 8162026 | 31 |
| MDYV | State Street SPDR S&P 400 Mid Cap Value ETF | -6.0% | 91.53 | 9162026 | 97.39 | 8162026 | 31 |
| VBR | Vanguard Small-Cap Value ETF | -5.1% | 238.83 | 9162026 | 251.66 | 8162026 | 31 |
| IWN | iShares Russell 2000 Value ETF | -5.1% | 215.86 | 9162026 | 227.43 | 8162026 | 31 |
| IJS | iShares S&P Small-Cap 600 Value ETF | -6.0% | 132.23 | 9162026 | 140.68 | 8162026 | 31 |
| SLYV | State Street SPDR S&P 600 Small Cap Value ETF | -5.6% | 105.94 | 9162026 | 112.22 | 8162026 | 31 |
| VIOV | Vanguard S&P Small-Cap 600 Value ETF | -5.6% | 114.02 | 9162026 | 120.76 | 8162026 | 31 |
| IEMG | iShares Core MSCI Emerging Markets ETF | -6.8% | 80.11 | 9162026 | 86.00 | 6222026 | 86 |
| EEM | iShares MSCI Emerging Markets ETF | -7.7% | 65.72 | 9162026 | 71.21 | 6222026 | 86 |
| ASHR | Xtrackers Harvest CSI 300 China A-Shares ETF | -10.8% | 33.28 | 9162026 | 37.30 | 6222026 | 86 |
| EWY | iShares MSCI South Korea ETF | -19.9% | 175.54 | 9162026 | 219.20 | 6212026 | 87 |
| EWZ | iShares MSCI Brazil ETF | -10.2% | 37.48 | 9162026 | 41.73 | 4142026 | 155 |
| FXI | iShares China Large-Cap ETF | -11.3% | 33.92 | 9162026 | 38.26 | 5132026 | 126 |
| ILF | iShares Latin America 40 ETF | -8.1% | 35.03 | 9162026 | 38.10 | 4142026 | 155 |
| KWEB | KraneShares CSI China Internet ETF | -20.8% | 24.24 | 9162026 | 30.59 | 5132026 | 126 |
| CGDV | Capital Group Dividend Value ETF | -5.6% | 48.55 | 9162026 | 51.44 | 8132026 | 34 |
| NOBL | ProShares S&P 500 Dividend Aristocrats ETF | -5.5% | 55.85 | 9162026 | 59.07 | 8242026 | 23 |
| MTUM | iShares MSCI USA Momentum Factor ETF | -13.1% | 299.83 | 9162026 | 345.22 | 6222026 | 86 |
| SPHQ | Invesco S&P 500 Quality ETF | -7.9% | 82.95 | 9162026 | 90.10 | 6302026 | 78 |
| FNDA | Schwab Fundamental U.S. Small Company ETF | -6.9% | 35.88 | 9162026 | 38.52 | 8162026 | 31 |
| SPMO | Invesco S&P 500 Momentum ETF | -11.1% | 143.66 | 9162026 | 161.66 | 6222026 | 86 |
| URA | Global X Uranium ETF | -29.0% | 41.37 | 9162026 | 58.26 | 5062026 | 133 |
| BOTZ | Global X Funds Global X Robotics & Artificial Intelligence ETF | -16.6% | 34.72 | 9162026 | 41.63 | 5132026 | 126 |
| ROBO | ROBO Global Robotics & Automation Index ETF | -14.1% | 77.56 | 9162026 | 90.34 | 6022026 | 106 |
| LIT | Global X Lithium & Battery Tech ETF | -23.8% | 69.85 | 9162026 | 91.62 | 5112026 | 128 |
| ICLN | iShares Global Clean Energy ETF | -27.1% | 17.32 | 9162026 | 23.75 | 6022026 | 106 |
| ARKQ | ARK Autonomous Technology & Robotics ETF | -17.0% | 119.39 | 9162026 | 143.82 | 5282026 | 111 |
| ARKX | ARK Space & Defense Innovation ETF | -16.3% | 31.58 | 9162026 | 37.74 | 5282026 | 111 |
| NASA | Tema Space Innovators ETF | -44.6% | 23.20 | 9162026 | 41.89 | 5272026 | 112 |
| AGIX | KraneShares Artificial Intelligence ETF | -9.1% | 44.92 | 9162026 | 49.40 | 6012026 | 107 |
| DRSK | Aptus Defined Risk ETF | -6.7% | 27.69 | 9162026 | 29.67 | 6012026 | 107 |
| YYY | Amplify CEF High Income ETF | -7.0% | 10.75 | 9162026 | 11.56 | 7122026 | 66 |
| GDE | WisdomTree Efficient Gold Plus Equity Strategy Fund | -9.2% | 64.72 | 9162026 | 71.30 | 8252026 | 22 |
| VGT | Vanguard Information Technology ETF | -5.3% | 118.92 | 9162026 | 125.62 | 6022026 | 106 |
| XLK | State Street Technology Select Sector SPDR ETF | -7.2% | 183.93 | 9162026 | 198.21 | 6022026 | 106 |
| XLI | State Street Industrial Select Sector SPDR ETF | -9.5% | 168.71 | 9162026 | 186.51 | 8162026 | 31 |
| XLC | State Street Communication Services Select Sector SPDR ETF | -5.1% | 113.00 | 9162026 | 119.10 | 4192026 | 150 |
| XLY | State Street Consumer Discretionary Select Sector SPDR ETF | -9.7% | 110.18 | 9162026 | 122.06 | 5282026 | 111 |
| XLU | State Street Utilities Select Sector SPDR ETF | -12.4% | 41.32 | 9162026 | 47.15 | 4092026 | 160 |
| XLB | State Street Materials Select Sector SPDR ETF | -6.2% | 50.36 | 9162026 | 53.67 | 8262026 | 21 |
| IYJ | iShares U.S. Industrials ETF | -8.5% | 155.36 | 9162026 | 169.86 | 8042026 | 43 |
| IYM | iShares U.S. Basic Materials ETF | -7.3% | 182.17 | 9162026 | 196.45 | 8252026 | 22 |
| SMH | VanEck Semiconductor ETF | -18.4% | 545.56 | 9162026 | 668.91 | 6222026 | 86 |
| SOXX | iShares Semiconductor ETF | -23.4% | 502.06 | 9162026 | 655.01 | 6222026 | 86 |
| IBB | iShares Biotechnology ETF | -6.7% | 202.40 | 9162026 | 216.96 | 8192026 | 28 |
| XBI | State Street SPDR S&P Biotech ETF | -9.1% | 154.18 | 9162026 | 169.55 | 8192026 | 28 |
| ITA | iShares U.S. Aerospace & Defense ETF | -15.0% | 215.27 | 9162026 | 253.22 | 8162026 | 31 |
| IYT | iShares U.S. Transportation ETF | -10.9% | 80.16 | 9162026 | 90.01 | 7162026 | 62 |
| IAI | iShares U.S. Broker-Dealers & Securities Exchanges ETF | -8.5% | 181.16 | 9162026 | 198.06 | 9032026 | 13 |
| KRE | State Street SPDR S&P Regional Banking ETF | -6.7% | 72.74 | 9162026 | 77.93 | 8162026 | 31 |
| MISL | First Trust Indxx Aerospace & Defense ETF | -13.6% | 42.50 | 9162026 | 49.19 | 5282026 | 111 |
| RING | iShares MSCI Global Gold Miners ETF | -12.4% | 81.58 | 9162026 | 93.17 | 8252026 | 22 |
| SOXQ | Invesco PHLX Semiconductor ETF | -23.1% | 88.57 | 9162026 | 115.11 | 6222026 | 86 |
| TLT | iShares 20+ Year Treasury Bond ETF | -6.8% | 80.88 | 9162026 | 86.78 | 6292026 | 79 |
| VGLT | Vanguard Long-Term Treasury ETF | -5.9% | 51.89 | 9162026 | 55.12 | 6292026 | 79 |
| SPTL | State Street SPDR Portfolio Long Term Treasury ETF | -6.2% | 24.69 | 9162026 | 26.33 | 6292026 | 79 |
| TLH | iShares 10-20 Year Treasury Bond ETF | -5.6% | 94.93 | 9162026 | 100.56 | 6292026 | 79 |
| EDV | Vanguard World Funds Extended Duration ETF | -9.3% | 59.31 | 9162026 | 65.43 | 6242026 | 84 |
| VCLT | Vanguard Long-Term Corporate Bond ETF | -5.2% | 70.93 | 9162026 | 74.85 | 6292026 | 79 |
| SPLB | State Street SPDR Portfolio Long Term Corporate Bond ETF | -5.8% | 21.11 | 9162026 | 22.40 | 6292026 | 79 |
| IGLB | iShares 10+ Year Investment Grade Corporate Bond ETF | -5.6% | 47.25 | 9162026 | 50.05 | 6292026 | 79 |
| LMUB | iShares Long-Term National Muni Bond ETF | -6.5% | 47.71 | 9162026 | 51.00 | 7052026 | 73 |
| GSG | iShares GSCI Commodity | -5.8% | 30.01 | 9162026 | 31.85 | 3182026 | 182 |
| GLD | SPDR Gold Trust | -12.2% | 391.74 | 9162026 | 445.93 | 4192026 | 150 |
| IAU | iShares Gold Trust | -12.1% | 80.32 | 9162026 | 91.34 | 4192026 | 150 |
| GLDM | SPDR Gold MiniShares Trust | -12.0% | 84.53 | 9162026 | 96.04 | 4192026 | 150 |
| BAR | Direxion Daily Gold Bull 3X Shares | -7.0% | 44.34 | 9162026 | 47.68 | 3182026 | 182 |
| SLV | iShares Silver Trust | -28.1% | 57.05 | 9162026 | 79.35 | 5132026 | 126 |
| PPLT | ETFS Physical Platinum Shares | -19.0% | 15.83 | 9162026 | 19.55 | 5132026 | 126 |
| PALL | ETFS Physical Palladium Shares | -20.0% | 23.11 | 9162026 | 28.89 | 4142026 | 155 |
| UNG | United States Natural Gas Fund LP | -18.2% | 10.36 | 9162026 | 12.67 | 3182026 | 182 |
| BNO | United States Brent Oil Fund LP ETV | -7.1% | 55.85 | 9162026 | 60.13 | 5042026 | 135 |
| VNQ | Vanguard Real Estate ETF | -7.4% | 93.48 | 9162026 | 100.95 | 7282026 | 50 |
| XLRE | State Street Real Estate Select Sector SPDR ETF | -7.0% | 42.81 | 9162026 | 46.01 | 7282026 | 50 |
| SCHH | Schwab U.S. REIT ETF | -8.0% | 22.88 | 9162026 | 24.86 | 7262026 | 52 |
| IYR | iShares U.S. Real Estate ETF | -8.0% | 98.65 | 9162026 | 107.26 | 7282026 | 50 |
| REET | iShares Global REIT ETF | -8.8% | 26.36 | 9162026 | 28.89 | 7262026 | 52 |
| USRT | iShares Core U.S. REIT ETF | -9.5% | 63.16 | 9162026 | 69.82 | 7262026 | 52 |
| IBIT | iShares Bitcoin Trust ETF | -7.4% | 43.04 | 9162026 | 46.47 | 5112026 | 128 |
| FBTC | Fidelity Wise Origin Bitcoin Fund | -7.4% | 66.10 | 9162026 | 71.35 | 5112026 | 128 |
| ETHA | iShares Ethereum Trust ETF | -5.3% | 18.15 | 9162026 | 19.17 | 9142026 | 2 |
ETF Fund Flows
Largest fund inflows and outflows across ETFs, with the asset-allocation rotation they imply.
Asset allocation rotation · Past month
- Equity ETFs drew the largest net inflows (+$62.6B), followed by Bond (+$15.1B), while Real Estate (−$143M) saw the largest outflows.
- Within the mix, money rotated into US Mid Cap Core (+$11.0B) and out of US Large Cap Core (−$10.6B).
- Relative to fund size, CNEQ drew the largest inflow (+73.8% of AUM) and SNXX the largest outflow (−32.3%).
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | VOO | Vanguard S&P 500 ETF | +$57.4B | +5.5% |
| 2 | VTI | Vanguard Morningstar Total Stock Market ETF | +$9.38B | +1.4% |
| 3 | SGOV | iShares 0-3 Month Treasury Bond ETF | +$7.25B | +6.8% |
| 4 | SPMO | Invesco S&P 500 Momentum ETF | +$7.15B | +32.2% |
| 5 | SCHD | Schwab U.S. Dividend Equity ETF | +$6.03B | +5.4% |
| 6 | SMH | VanEck Semiconductor ETF | +$4.63B | +6.8% |
| 7 | VGSH | Vanguard Short-Term Treasury ETF | +$4.52B | +13.1% |
| 8 | VUG | Vanguard Morningstar Growth ETF | +$4.43B | +2.0% |
| 9 | GLD | SPDR Gold Shares | +$4.06B | +2.7% |
| 10 | VO | Vanguard Morningstar Mid-Cap ETF | +$4.04B | +3.7% |
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | IVV | iShares Core S&P 500 ETF | -$50.76B | -5.8% |
| 2 | SPY | State Street SPDR S&P 500 ETF | -$20.78B | -2.6% |
| 3 | LQD | iShares iBoxx $ Investment Grade Corporate Bond ETF | -$5.08B | -16.1% |
| 4 | QQQ | Invesco QQQ Trust, Series 1 | -$4.21B | -0.9% |
| 5 | HYG | iShares iBoxx $ High Yield Corporate Bond ETF | -$2.82B | -18.0% |
| 6 | VGIT | Vanguard Intermediate-Term Treasury ETF | -$2.39B | -6.0% |
| 7 | DRAM | Roundhill Memory ETF | -$2.29B | -8.8% |
| 8 | XLF | State Street Financial Select Sector SPDR ETF | -$2.27B | -4.1% |
| 9 | EWY | iShares MSCI South Korea ETF | -$1.91B | -6.9% |
| 10 | GOVT | iShares U.S. Treasury Bond ETF | -$1.59B | -3.8% |
Largest ETF fund flows across ~2634 funds (min AUM $100M). Net creations/redemptions; leveraged & inverse ETFs excluded. A ⚠ marks a day excluded as a suspected data error.
About XBI
| Holdings Count: 154Expense Ratio: 0.35%Inception Date: 2006-01-31 | State Street SPDR S&P Biotech ETFSPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.Asset Class: Equity | ETF Website |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| These Funds Are Suddenly Outperforming Themselves | 07/17/2026 | |
| XBI Ignored The Market's Downturn | 06/27/2026 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Profile
| Median | |
|---|---|
| Name | |
| Asset Class | - |
| AUM ($ Bil) | 11.7 |
| Expense Ratio | 0.35% |
| 10-D Avg Volume (Mil) | 6.04 |
| Latest Day Volume (Mil) | 6.25 |
| Holdings Count | 50 |
| Inception Date | - |
Fundamentals
| Median | |
|---|---|
| Name | |
| Net Asset Value | - |
| Premium/Discount | -1.8% |
| Distribution Yield | 0.2% |
| Sales Yield | 10.6% |
| Earnings Yield | 2.3% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.